Vyepti Success Rate for Episodic and Chronic Migraine

Vyepti (eptinezumab) reduces monthly migraine days by a meaningful margin in most people who try it, though “success” depends on how you measure it and how severe your migraines are to begin with. In the pivotal clinical trials, roughly half to three-quarters of patients with chronic migraine experienced at least a 30% reduction in migraine days over 12 weeks, and those numbers improved with continued treatment. The drug stands out from other preventive migraine therapies in a couple of ways worth understanding, especially its speed of onset and its track record in people who have already failed other treatments.

What Vyepti Is and How It Works

Vyepti is a monoclonal antibody that targets calcitonin gene-related peptide, or CGRP, a molecule heavily involved in migraine attacks. It binds to CGRP and blocks it from reaching its receptor, essentially intercepting one of the key chemical signals that triggers and sustains migraine pain. The drug was approved in the United States in February 2020 for the preventive treatment of migraine in adults.¹

What makes Vyepti distinct from the other CGRP-targeting preventives on the market is that it is given as an intravenous infusion rather than a self-administered injection. You receive it in a healthcare setting, typically over about 30 minutes, once every three months. That delivery method matters for the success-rate conversation because it eliminates the issue of patients forgetting doses or injecting incorrectly, and it gets the drug into the bloodstream immediately at full concentration.

Episodic Migraine Trial Results

The first major efficacy trial, called PROMISE-1, enrolled people with episodic migraine, meaning they experienced between 4 and 14 migraine days per month. Over the first 12 weeks, both the 100 mg and 300 mg doses produced statistically significant reductions in monthly migraine days compared to placebo. The 300 mg dose showed the larger effect, with roughly one additional migraine day eliminated per month beyond what placebo achieved.²

One thing that catches people off guard is the placebo response in migraine trials, which tends to be large. In PROMISE-1, the placebo group also improved, so the net difference between drug and placebo looks modest as a raw number. But in migraine prevention, a placebo-adjusted reduction of about one day per month is considered clinically meaningful, and the proportion of patients who crossed thresholds like a 50% or 75% reduction in migraine days was consistently higher in the Vyepti groups.

Chronic Migraine Trial Results

The numbers become more dramatic in chronic migraine, where patients have 15 or more headache days per month. In the PROMISE-2 trial, people receiving Vyepti 100 mg saw their monthly migraine days drop by about 7.7 days over 12 weeks, and those on 300 mg saw a reduction of about 8.2 days. The placebo group dropped by 5.6 days, making the drug’s advantage over placebo roughly 2 to 2.5 fewer migraine days per month.³

Looking at responder rates tells a more practical story. During the first 12 weeks, the odds of achieving at least a 50% reduction in migraine days were roughly double for the 100 mg group and about 2.4 times higher for the 300 mg group, compared to placebo. The odds of reaching 75% reduction were even more strongly tilted toward the drug.⁴ Both dose levels met the primary efficacy endpoints across key secondary measures as well.⁵

How Quickly It Starts Working

Speed of onset is one of Vyepti’s most notable features. Because the drug is infused directly into the bloodstream, it reaches therapeutic levels faster than subcutaneous injections, which absorb more gradually. In the PROMISE-2 trial, the separation from placebo in the 75% responder rate was already apparent during the first four weeks of treatment.⁶

Even more striking is what happens when Vyepti is given during an active migraine attack. In the RELIEF trial, patients who received their first Vyepti infusion while experiencing a migraine reported faster resolution than those given placebo. Within one hour, about 10% of the Vyepti group was headache-free compared to 4% on placebo. By two hours, about 24% of Vyepti patients were pain-free versus 12% on placebo. The median time to complete headache freedom was 4 hours with Vyepti versus 9 hours with placebo.⁷ Fewer Vyepti-treated patients needed rescue medication within 24 hours as well, with about 32% reaching for backup treatment versus 60% in the placebo group.⁸

This rapid onset also showed up as early as one hour post-infusion in another analysis of the same trial data, with significantly more Vyepti patients achieving headache pain relief and absence of their most bothersome symptom compared to placebo at that early time point.⁹ To be clear, Vyepti is approved as a preventive, not an acute treatment. But the fact that it can start working on the very day of infusion is a meaningful practical advantage for people living with frequent attacks.

Results in People Who Have Already Failed Other Preventives

Many people considering Vyepti have already tried and been disappointed by other migraine preventives, whether older medications like topiramate and beta-blockers or other CGRP-targeted therapies. The DELIVER trial was designed specifically for this population, enrolling patients who had failed two to four prior preventive treatments.

Over the first 12 weeks, about 66% of patients on Vyepti 100 mg and 71% on 300 mg achieved at least a 30% reduction in migraine days, compared to roughly 37% on placebo. By weeks 13 through 24, those numbers climbed further. A particularly interesting finding was what happened to initial non-responders: among patients who did not reach a 30% reduction during the first 12 weeks, about a third of those on either Vyepti dose went on to become responders after their second infusion, compared to 21% with placebo.¹⁰

The long-term extension of DELIVER followed patients for up to 72 weeks. By the end, about 63 to 70% of patients on Vyepti demonstrated at least a 50% reduction in monthly migraine days, and 36 to 45% achieved a 75% reduction. The mean reduction from baseline in monthly migraine days reached about 6.4 to 7.3 days by the final dosing interval.¹¹ For a group of patients who had already been failed by multiple treatments, those are encouraging numbers.

Long-Term Maintenance Over Two Years

A separate open-label trial called PREVAIL tracked patients with chronic migraine who received Vyepti 300 mg every 12 weeks for nearly two years, through week 84, with follow-up continuing to week 104. Over half of the patients who achieved at least a 50% reduction in headache days after their first dose sustained that level of improvement through every subsequent dosing interval until the last infusion.¹²

By week 104, more than 60% of participants were experiencing fewer than four headache days per month, a threshold that effectively means moving from chronic to episodic migraine. Perhaps most striking, about 23% reported zero headache days at that point. Disability scores, measured by a functional severity index, dropped sharply after the first infusion and stayed low through the end of follow-up.¹³ These results suggest that for people who respond, the benefit holds up with continued dosing rather than wearing off over time.

Medication Overuse Headache

One of the trickiest situations in migraine management is when frequent use of acute medications (triptans, NSAIDs, combination painkillers) actually starts causing more headaches. This cycle of medication overuse headache, or MOH, is common in people with chronic migraine and makes the whole picture harder to treat. Doctors often tell patients they need to stop their acute medications to break the cycle, which is easier said than done when you are in severe pain multiple times a week.

Vyepti has shown clear benefits in this population. In the RESOLUTION trial, which specifically enrolled people with chronic migraine and medication overuse headache, patients who received Vyepti alongside structured patient education had a reduction of about 6.9 migraine days per month during the first four weeks, compared to 3.7 days in the placebo-plus-education group. That three-day advantage was sustained through 12 weeks.¹⁴ More patients in the Vyepti group stopped meeting the criteria for either chronic migraine or medication overuse headache over the course of the study, and the severity of attacks went down alongside the frequency.¹⁵

Real-World Results Outside Clinical Trials

Clinical trials recruit carefully selected patients and run under controlled conditions, so the question of whether results hold up in everyday practice always matters. Several real-world studies have now addressed this for Vyepti, and the findings are broadly consistent with the trial data, though with the kind of messiness you expect in typical clinical populations.

In the US-based REVIEW observational study, patients with chronic migraine reported going from an average of about 8 “good” days per month before Vyepti to 18 good days after treatment. The proportion of patients using prescription acute medication on 10 or more days per month dropped from 81% before treatment to 26% afterward. Over-the-counter medication use fell similarly.¹⁶ That shift in acute medication use is not just a side benefit; it reduces the risk of developing medication overuse headache and lowers the overall treatment burden.

A large French registry tracked patients who were considered difficult to treat and who had not previously used any CGRP monoclonal antibody. The 50% responder rate at three months was about 35%, which climbed to 39% at six months and 46% at 12 months. Looking at a less stringent threshold, about 49% of patients achieved at least a 30% reduction at three months, rising to 63% by one year. The proportion of patients who rated themselves “much improved” or “very much improved” grew from 42% at three months to 74% at one year.¹⁷ The gradual improvement over time is worth noting: if your initial response seems underwhelming, the data suggests it may still build with subsequent infusions.

Switching From Other CGRP Therapies

A common real-world scenario is a patient who tried one of the self-injected CGRP antibodies (erenumab, fremanezumab, or galcanezumab) and did not get enough relief, then switches to Vyepti. Some clinicians are skeptical that switching within the same drug class would help, since all these medications target the same pathway. But the data suggests it can work.

In a real-world study of 94 patients with chronic migraine, 89% had previously used a subcutaneous CGRP antibody. After switching to Vyepti, these patients gained an average of about 9 to 11 additional good days per month regardless of which prior CGRP therapy they had used, and regardless of whether they had failed one, two, or even three prior antibodies.¹⁸ The intravenous route likely plays a role here: it bypasses the subcutaneous absorption pathway, delivers the full dose immediately, and may reach higher peak concentrations faster. There may also be molecular differences in how eptinezumab binds CGRP compared to the other antibodies in its class.

Quality of Life Beyond Counting Migraine Days

Migraine days per month is the standard clinical outcome, but it misses a lot. A day that technically does not meet the criteria for a “migraine day” can still be miserable if you are dealing with brain fog, fatigue, anxiety about the next attack, or residual sensitivity to light and noise. Quality-of-life measures try to capture this broader picture.

In the DELIVER trial population (patients with prior treatment failures), Vyepti improved overall health ratings, headache-related quality of life, and every domain of a migraine-specific quality-of-life questionnaire. Over twice as many Vyepti patients as placebo patients reported feeling “much improved” or “very much improved” on a global impression scale.¹⁹ These improvements started as early as four weeks and were maintained at every subsequent assessment.

Brain fog specifically deserves mention. In the real-world study of chronic migraine patients, those who reported significant improvement in brain fog with Vyepti gained an average of 15 additional good days per month. Those who said their brain fog did not improve gained only about 1 additional good day.²⁰ This is an observational correlation rather than proof that Vyepti directly clears brain fog, but it does highlight how interconnected the cognitive symptoms are with overall treatment response.

Safety and Side Effects

Vyepti’s safety profile is one of its selling points. Across clinical trials, the most commonly reported side effects were nausea and fatigue, and hypersensitivity reactions were rare.²¹ The rate of patients dropping out due to adverse events was low across all the major trials. In the PREVAIL long-term study, which followed patients for two years, there were no new safety signals that emerged with extended use.²²

The infusion itself is the main practical hurdle. You need to go to a healthcare facility, which takes time out of your day, and some people feel anxious about IVs. In the REVIEW study, about 62% of patients said they were at least slightly concerned about infusions before starting Vyepti, but that number dropped to 14% after they had experienced one.²³ The quarterly dosing schedule also means you are dealing with this only four times a year rather than monthly.

Psychiatric Comorbidities and Treatment Response

Depression and anxiety are extremely common in people with chronic migraine, and there has long been a concern that psychiatric comorbidities might blunt the response to preventive therapies. For Vyepti, the real-world evidence suggests this is not a major issue. Among chronic migraine patients with psychiatric comorbidities (65% of the cohort in one study), the average gain in good days per month was about 9.8, essentially identical to the 10.1-day gain in patients without psychiatric conditions.²⁴ This is reassuring for the large share of migraine patients who live with co-occurring mood disorders and wonder whether a treatment will work for them as well as it does for the healthier-looking patients in trial populations.

The French real-world registry reinforced this picture from a different angle, showing that the functional and emotional impact of migraine, measured by anxiety and depression scales, interictal burden scores, and overall quality of life, all improved significantly at every time point through 12 months of Vyepti treatment.²⁵ Whether that is because fewer migraines lead to less depression, or because blocking CGRP has some independent effect on mood circuits, remains an open question. Either way, the practical takeaway is that having anxiety or depression should not be a reason to expect Vyepti will not work for you.